The rhabdomyosarcoma (RMS) is the most common type of soft tissue tumor in children and adolescents;yet only a few screens for oncogenic mutations have been conducted for RMS. To identify novel mutations andpotential therapeutic targets, we conducted a high-throughput Sequenom mass spectrometry-based analysis of238 known mutations in 19 oncogenes in 17 primary formalin-fixed paraffin-embedded RMS tissue samples andtwo RMS cell lines. Mutations were detected in 31.6% (6 of 19) of the RMS specimens. Specifically, mutations inthe NRAS gene were found in 27.3% (3 of 11) of embryonal RMS cases, while mutations in NRAS, HRAS, andPIK3CA genes were identified in 37.5% (3 of 8) of alveolar RMS (ARMS) cases; moreover, PIK3CA mutationswere found in 25% (2 of 8) of ARMS specimens. The results demonstrate that tumor profiling in archival tissuesamples is a useful tool for identifying diagnostic markers and potential therapeutic targets and suggests thatthese HRAS/ PIK3CA mutations play a critical role in the genesis of RMS.
(2014). Compound HRAS/PIK3CA Mutations in Chinese Patients with Alveolar Rhabdomyosarcomas. Asian Pacific Journal of Cancer Prevention, 15(4), 1771-1774.
MLA
. "Compound HRAS/PIK3CA Mutations in Chinese Patients with Alveolar Rhabdomyosarcomas". Asian Pacific Journal of Cancer Prevention, 15, 4, 2014, 1771-1774.
HARVARD
(2014). 'Compound HRAS/PIK3CA Mutations in Chinese Patients with Alveolar Rhabdomyosarcomas', Asian Pacific Journal of Cancer Prevention, 15(4), pp. 1771-1774.
VANCOUVER
Compound HRAS/PIK3CA Mutations in Chinese Patients with Alveolar Rhabdomyosarcomas. Asian Pacific Journal of Cancer Prevention, 2014; 15(4): 1771-1774.